Company ProfilePremium

Resonance Health Limited

Company Profile Analysis

Ticker: RHT.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Resonance Health Limited - Company showcase

Year Founded & Workforce

1987

Resonance Health Limited logo

Resonance Health Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Resonance Health Limited Overview

Resonance Health is a Perth-based micro-cap healthcare technology and clinical-services group. It has evolved from a single-product imaging-analysis company into an integrated, clinical-trial-centric platform. Its origin and reputational anchor is FerriScan, an MRI-based liver iron concentration (LIC) measurement cleared by the FDA, CE and TGA since 2005 and widely regarded as the reference standard in its niche. Around this core it has built a portfolio of regulated software-as-a-medical-device (SaMD) products covering liver iron, liver fat, cardiac iron and body composition, plus MRI elastography central reads.

Since FY24 the company has added a contract research organisation (Resonance Clinical) and a three-site investigator network in Western Australia (TrialsWest). Management describes these as three mutually referring businesses. In FY26 the group earned A$15.8M revenue (+42%) and returned to statutory profit (A$1.5M NPAT). Clinical-trial customers generated nearly 80% of revenue. A non-invasive MRI liver-fibrosis device in extended proof-of-concept is the main long-dated option.


Company's own description (FY26 Annual Report, paraphrased)

The FY26 Directors' Report describes the following:

  • The group was founded on developing and commercialising SaMD technologies and services for quantitative analysis of radiological images, delivered in a regulated, quality-controlled environment.

  • The core SaMD product is FerriScan®, a non-invasive liver iron assessment.

  • Other SaMDs include CardiacT2* (heart iron) and HepaFatScan® (liver fat), plus the AI-assisted devices FerriSmart®, HepaFatSmart® and LiverSmart®.

  • The group acts as CRO and local Australian sponsor on a clinical trial for a major global pharmaceutical company's new drug compound.

  • It operates a site management organisation trading as TrialsWest, with three trial sites in and around Perth.

The company holds ISO 13485 certification and regulatory clearances in the USA, Europe, UK and Australia. It reports three business focus areas:

  1. Clinical Trial Management (CRO) Services (Resonance Clinical)

  2. Clinical Trial Site Services (TrialsWest)

  3. Software-as-a-Medical-Device image analysis services (SaMD, also branded "Resonance Imaging")

Business and revenue model

RHT is a services business. Its intellectual property is delivered as a regulated analysis service, not as licensed software sold per seat.

SaMD / central imaging. Customers acquire MRI scans on their own scanners using RHT protocols and upload images. RHT analysts, increasingly assisted by AI, return a regulated quantitative report.

  • Revenue is recognised per completed analysis (point in time). Clinical-trial customers also pay multi-year contract fees covering trial establishment, data management and analysis.

  • The company describes this as a "Software as a Service" model (Nov 2019 investor presentation). In accounting terms it is fee-for-service.

  • A "voucher revenue" category appears in the revenue-recognition policy, but no amounts are disclosed separately.

Resonance Clinical (CRO / local sponsor). RHT contracts directly with pharmaceutical sponsors, so far Sun Pharmaceutical Industries, to act as Australian local sponsor and CRO. It manages sites, vendors, patient payments and data, and bundles in imaging reads.

  • Revenue is recognised over time on a cost-to-complete (input) basis.

  • This gives the segment large gross revenue but includes substantial pass-through costs (site and vendor payments).

TrialsWest (site management organisation). Investigator sites in Spearwood, Osborne Park and Mandurah recruit and treat trial participants for sponsors, including GSK, Pfizer, Novartis, Sanofi and MSD (FY26 CEO letter). It is paid per patient visit and procedure under sponsor clinical trial agreements.

Revenue mix by contract type (FY26 AR Note 5):

  • Over-time clinical-trial revenue: A$9.37M (59%)

  • Point-in-time commercial (diagnostic) revenue: A$3.22M (20%)

  • Point-in-time clinical-trial revenue: A$2.40M (15%)

  • Other studies: A$0.76M (5%)

No subscription or licensing revenue is disclosed. Effectively 100% of revenue is service revenue.

Customer types and end-markets

Customer typeDescriptionEvidence
Pharma and biotech sponsors (clinical trials)Imaging endpoints in iron-overload (thalassaemia, sickle cell, MDS), metabolic (MASLD/MASH, obesity / GLP-1) and other trials; CRO and site servicesClinical-trial customers were nearly 80% of FY26 revenue (FY26 AR)
Hospitals, haematology clinics, radiology / MRI centres (diagnostics)FerriScan / FerriSmart / HepaFat reports for patient management in chronic iron overload and fatty liver diseaseDiagnostic customers were under 20% of FY26 revenue; products used in over 244 hospitals and MRI centres in FY26 (FY26 AR)
Single largest customerMajor global pharma under the CRO agreements (Sun Pharmaceutical Industries per contemporaneous press coverage)48% of FY26 revenue (FY25: 38%; FY24: 45%) (FY26 / FY25 AR Note 4)

Value-chain position

RHT sits in the drug-development services value chain. It provides:

  • Imaging core-lab services, between the scanner (hardware OEMs) and the sponsor's endpoint analysis

  • Investigator-site services, at patient recruitment and treatment

  • CRO / local sponsorship, covering Australian trial conduct and regulatory sponsorship

In diagnostics it is a specialised quantitative post-processing provider sitting downstream of radiology practices. In the US it is reimbursed through private insurer codes, and in the UK, Germany and Canada through public systems (Stockhead, historical).

Independent characterisation

Analytically, RHT has three businesses with distinct economics.

  1. A high-margin niche imaging core lab. FY26 SaMD segment pre-tax profit margin was 46.6% on A$7.0M of segment revenue. It has deep scientific credibility in liver iron and a growing presence in metabolic imaging endpoints.

  2. A lumpy, single-customer-dependent CRO. Resonance Clinical earned A$7.5M revenue at a 13.4% segment margin in FY26, nearly all from one sponsor's MASH trial.

  3. A small but profitable investigator-site network. TrialsWest earned A$4.1M revenue at a 24.4% segment margin in FY26.

The investment case rests on two things. First, whether the "won once, earned three times" cross-referral flywheel produces repeatable CRO wins beyond Sun Pharma. Second, whether the SaMD core lab can scale volume through automation (the Resonance Bridge and AI tooling) without proportional headcount. The liver-fibrosis device is a free option that is not in guidance.

Strategy

Stated strategy themes (FY26 AR Chair and CEO letters, FY26 results; paraphrased)

Integrated three-business platform. Management presents Resonance Imaging (SaMD), Resonance Clinical (CRO) and TrialsWest (sites) as one integrated platform. A single sponsor contract can feed all three units; the CEO describes a contract as being "won once and earned three times" (FY26 CEO letter).

Structural tailwinds. The strategy is aligned to three forces: rising liver-disease prevalence, newly approved MASH therapies that need imaging, and the growth of GLP-1 and obesity trials.

Self-funded growth. The board treats funding growth from operations as the key test of the model. The liver-fibrosis device is developed from operating cash flow, and no fibrosis revenue is assumed in near-term plans.

FY27 priorities:

  1. Convert the SaMD pipeline (over A$12M of orders and bids, nearer A$13M per the FY26 webinar) and CRO opportunities into contracts.

  2. Deliver the fibrosis EPoC readout and progress toward investigational use.

  3. Let automation investments lift margins.

  4. Pursue site-network or geographic expansion selectively.

Initiatives in the last 24 months (Oct 2024 to Oct 2026)

InitiativeDateDetailStatus
A$13.775M Sun Pharma CRO / sponsor contract (MASH)Nov 2024Largest contract in company history; bundles CRO, site (TrialsWest) and imagingFully recruited (60 patients) Apr 2026; invoicing into FY27; budget reset Jun 2026
TrialsWest network expansionAug 2024 to Jul 2025Osborne Park and Mandurah sites triple capacityOsborne Park profitable; Mandurah near breakeven
Cost efficiency programmeAnnounced Aug 2025About A$1.1M annualised savingsEmployee cost / revenue fell from 51% to 41% in FY26
Exit of ASO molecular medicine; Bentley lab closureFY25Refocus on nearer-term commercialisationComplete
Resonance Bridge (PACS integration and automation)Commercial testing FY25; validated 1H FY26Targets 5–10x analysis capacityCustomer pilots continuing into FY27
AI automation of FerriScan / FerriSmart ML refinementOngoing5–10x scan-volume capability indicated by initial testingIn development
New imaging endpoints: MRE central read, VAT/SATFY25 to FY26Obesity and MASH trial endpointsMaterial contributors to FY26 growth
MRI Liver Fibrosis EPoCMulti-year; enrolment completed 1H FY26Readout expected early FY27; regulatory plan in preparationAnalysis underway
India business development1H FY26Dedicated BD manager appointedEarly stage
China healthcare-provider discussions1H FY26Provision of RHT services in ChinaDiscussions only
Investor communications (InvestorHub, webinars, Strategy Day)FY25 to FY26Strategy Day 13 Oct 2025; fibrosis webinar 9 Jun 2026Ongoing
Board renewalNov 2025 to Apr 2026New Chair; two independent NEDs with pharma and capital-markets skillsComplete
Reimbursement push for commercial diagnosticsStated FY26Address flat diagnostic revenueNot quantified

Medium-term targets

TargetDetailSource
FY27 guidanceRevenue A$17–22M (+8% to +39%); normalised EBITDA A$2.6–3.6MFY26 results
Medium-term objectiveScale revenue toward A$30M at an underlying EBITDA margin of about 25%FY26 results; May 2026 upgrade
"Project 50:28"Aspiration to grow from about A$16M to A$50M revenue by end of FY28, with each dollar tied to a named driverFY26 CEO letter
Leverage policyNet debt / EBITDA not to exceed 2xFY26 earnings call (Investing.com)
Fibrosis deviceInvestigational use in pharma trials from FY27/28; commercial clearance thereafterFY26 AR; Jun 2026 webinar

FY27 guidance assumptions:

  • No new TrialsWest sites

  • One new CRO contract win

  • No acquisitions or geographic expansion

  • No fibrosis revenue

  • Existing trials run to full duration

ESG and sustainability commitments

None publicly disclosed.

Products & Services

SaMD segment (Resonance Imaging)

ProductDescription and capabilitiesRegulatory statusTarget customerLaunch / latest versionPricing
FerriScan®Core-lab MRI R2-based measurement of liver iron concentration (LIC). Produces mean LIC plus a colour-coded iron distribution map from about a 10-minute scan. Analysed by RHT staff in Perth, with results in about two business days. Described as the international gold standard for LIC. Over 70,000 patient analyses since launch (FY23 CEO letter). 3T compatibility added Aug 2022. A shortened protocol targeting about 75% less scan time is in validationFDA, CE, TGA (2005); Health Canada; FDA companion diagnostic for Exjade in NTDT (2013)Haematologists managing thalassaemia, sickle cell, MDS and haemochromatosis; trial sponsors developing chelators and iron-related drugs2005; 3T version 2022Per-analysis fee; not publicly disclosed. Reimbursed in UK, Germany and Canada, with US private-insurer codes (Stockhead, historical)
FerriSmart®AI / machine-learning automated LIC from MRI, calibrated against FerriScan. Returns results within seconds and works across most scanner makes and models. Deployed via RHT's web portal and channel partners. Ongoing ML refinement aims to raise FerriScan analysis productivity 5–10xTGA, CE (Jul 2018); FDA 510(k) (FY19)Radiology departments wanting real-time LIC; high-volume markets2018–2019—
HepaFatScan® (HepaFat-Scan)MRI liver-fat assessment. Reporting was upgraded in FY24 to a multi-metric report with PDFF (proton density fat fraction), VLFF (volumetric liver fat fraction), steatosis grade and fat distribution mapTGA, CE, FDA (FDA clearance referenced in FY2012 AR)Hepatologists; MASLD/MASH and obesity trial sponsorsc. 2012; enhanced FY24—
HepaFatSmart® (formerly HepaFat-AI®)AI-trained automated real-time liver-fat assessment providing VLFF, PDFF and steatosis gradeHepaFat-AI FDA Dec 2020; HepaFatSmart FDA FY23As aboveFY23—
LiverSmart®AI multi-parametric device combining FerriSmart and HepaFatSmart into one consolidated LIC plus liver-fat reportRegulatory-cleared per FY26 AR (jurisdictions not itemised)Hepatology and haematology——
CardiacT2*MRI T2* cardiac iron assessment; offered as a dual analysis with FerriScan. A 3T version is technically complete and available in trials; regulatory submission planned (FY24 AR)TGA, CEHaematology; iron-overload trialsNot publicly disclosed; 3T version FY24—
MRE central read (Magnetic Resonance Elastography)Central-read service for MRE liver-stiffness endpoints in clinical trialsService (no separate device clearance disclosed)MASH and obesity trial sponsorsCommenced FY25; scaled FY26Contract-based
VAT & SAT quantificationVisceral and subcutaneous adipose tissue volume quantification for body-composition endpointsServiceGLP-1 / obesity trial sponsorsFirst customer FY25; material revenue in FY26Contract-based
Resonance BridgeIn-house technology integrating RHT systems with customers' PACS. Removes personal health information from images and reports, automates workflow, and targets 5–10x analysis capacityWorkflow technologyImaging-site customersCommercial testing FY25; validated 1H FY26; first deployments FY26–FY27—
MRI Liver Fibrosis device (development)Multi-parametric MRI on standard hardware; 15-minute non-contrast scan; designed to neutralise iron, fat and inflammation confounders. EPoC fully enrolled with all MRI and biopsy data received; analysis underway. A secondary source reports 68 patients and an F0 vs F1+ signal (StockWireX; Jun 2026 presentation coverage)Not cleared. Targets investigational use in pharma trials from FY27/28, then commercial clearanceMASH and fibrosis trial sponsors; hepatologyDevelopmentNot applicable

Resonance Clinical segment

ServiceDescriptionFlagship engagement
Australian local sponsorActs as the Australian regulatory sponsor for foreign pharma trialsSun Pharma trials (2023, 2024)
CRO / trial managementSite selection and payments, vendor management, project and data management, trial establishmentA$6.33M contract (Aug 2023; final clinical study report issued 1H FY26). A$13.775M MASH contract (Nov 2024; 60 patients recruited Apr 2026; invoicing into FY27)
Bundled imagingCentral imaging reads at protocol timepoints, delivered by the SaMD segmentIncluded in the A$13.8M contract

Cumulative major-pharma CRO contract wins since August 2023 total A$20.1M (FY26 results).

TrialsWest segment

SiteStatusPerformance
Spearwood WA (original site; 6 Barrington Street per CB Insights)Operating since 2012Performing at pre-acquisition levels (FY26 AR)
Osborne Park WAAnnounced Aug 2024Consistently profitable; annualised revenue run-rate above A$2M; A$1.6M FY26 revenue
Mandurah WAOpened Jul 2025Close to breakeven in year one; ahead of plan

Therapeutic heritage is respiratory (asthma, COPD, chronic cough), vaccines and metabolic. Expansion is targeted at metabolic/endocrine and oncology. TrialsWest was running more than 25 studies at acquisition (BioXconomy, 2024) and more than 20 active trials in FY26 (FY26 CEO letter).

Discontinued

Molecular medicine / ASO (antisense oligonucleotide) programme. This programme developed cyclophilin-type-specific drug molecules for liver and neurological disease. It ceased in FY25, and the Bentley laboratory was closed and its lease surrendered in August 2025 (FY25 AR).

Financial Narrative

All figures are AUD, from audited statements in the FY23–FY26 Annual Reports.

Income statement

Notes:

  • Gross profit is not publicly disclosed; the P&L is presented by nature of expense.

  • FY22–FY23 finance costs are not separately disclosed (lease interest is embedded in other expenses), so those cells are blank.

  • FY21 revenue was A$3.779M and FY21 NPAT A$0.586M (FY25 AR five-year table).

Margins (analyst-computed)

Revenue CAGR:

  • FY22 to FY26 (4 years): 42.4%

  • FY23 to FY26: 52.9%

  • FY21 to FY26 (5 years): about 33.0%

Balance sheet (30 June)

Notes:

  • FY24 goodwill of A$7.26M was provisional. On finalisation of purchase-price accounting (FY25 AR) it was split into goodwill A$5.25M, customer contracts/relationships A$1.81M and patient database A$0.20M, with a further A$19.5k of goodwill added in FY25.

  • Accumulated losses were A$63.5M at 30 Jun 2026 (FY26 AR).

Cash flow

Notes:

  • Company-reported FCF was A$2.8M in FY26 and A$1.1M in FY25 (FY26 results announcement). The analyst figure deducts capitalised development, which the company's measure appears to exclude.

  • The FY24 buyback of 20M Acuity collateral shares was for nil consideration.

  • In FY25 the TrialsWest outflow of A$3.91M settled almost all of the A$4.0M deferred / earn-out consideration that had been carried as a current liability at 30 Jun 2024. Only A$85k of deferred consideration remains on the FY25 and FY26 balance sheets.

Ratios (analyst-computed, year-end balances)

Notes:

  • Blank cells are not meaningful: net cash combined with negative EBITDA, or finance costs not separately disclosed.

  • The company reports "underlying ROIC" of about 18% in FY26 and about 5% in FY25. That measure is pre-tax, uses normalised EBITDA less D&A, and divides by invested capital (FY26 results). It differs from the after-tax analyst figure above.

  • A cash conversion cycle is not meaningful because there is no inventory. Payables days are not computed because the cost-of-sales base is undisclosed.

Commentary on trends, inflections and drivers

Revenue: three distinct phases.

  • FY21–FY23 was stagnation at A$3.8–4.4M, essentially FerriScan diagnostic and trial reads.

  • FY24 brought a step change (+95%) as the first Sun Pharma CRO contract booked A$3.8M and TrialsWest contributed one month.

  • FY25–FY26 compounded growth (+29% then +42%) from the larger MASH contract, the full-year and then multi-site TrialsWest, and a renewed SaMD trial-imaging cycle driven by metabolic and obesity endpoints.

The quality of growth is improving at the segment level. Organic SaMD grew 33.5% in FY26. However, group revenue concentration also rose: the largest customer was 48% of FY26 revenue.

Profitability: the FY26 inflection is real but uneven within the year.

  • 1H FY26 delivered A$8.0M revenue, A$1.6M normalised EBITDA (20% margin) and A$1.5M NPAT (1H FY26 results).

  • Full-year FY26 delivered A$15.75M revenue, A$2.55–2.6M normalised EBITDA and A$1.51M NPAT.

  • That implies 2H FY26 of roughly A$7.75M revenue, about A$1.0M normalised EBITDA (about 13% margin) and approximately breakeven NPAT (analyst derivation).

The second-half softening matches the June 2026 MASH budget reset disclosed in the CEO letter and argues for caution in extrapolating the 1H run-rate.

Positive margin drivers:

  • Employee costs fell from 51% to 41% of revenue.

  • Expensed R&D fell from A$0.96M to A$0.43M.

  • Marketing and travel roughly halved, from A$0.86M to A$0.42M.

The offsetting drag is consulting and professional services, which rose from A$2.85M to A$4.03M. This line likely includes CRO pass-through and vendor costs; the FY26 AR does not itemise it.

Investors should treat the FY26 "+83% EBITDA growth" headline as measured against the adjusted A$1.4M base, not the statutory base.

Tax. RHT has reported an income tax benefit every year because of R&D tax incentive refunds of A$0.41–0.83M a year. FY26 is the first year with meaningful current tax payable (A$0.43M) and a recognised deferred tax asset (A$0.12M). Pre-tax profit (A$1.10M) is the cleaner measure of earnings power.

Balance sheet.

  • The TrialsWest acquisition, about A$8M including earn-out, converted a cash-rich, debt-free balance sheet (A$6.8M cash in FY22) into a modestly geared one.

  • Cash bottomed at A$3.0M in FY25 after the earn-out was effectively paid early.

  • FY26 operating cash generation rebuilt cash to A$4.85M against A$2.53M of NAB debt.

The key near-term item is that the entire NAB facility (A$2.53M, BBSY + 2.5%, secured over all group assets) is now classified as current because it expires 31 March 2027. Working capital has therefore compressed to A$0.88M and the current ratio to 1.13x. Management states renewal will be addressed well ahead of maturity.

Cash conversion. FY26 cash receipts (A$14.28M) trailed revenue (A$15.75M). This happened because the unearned income balance unwound from A$3.20M to A$1.23M: cash collected in advance in FY25 was recognised as revenue in FY26. DSO improved sharply to 50 days. The FY25 cash flow was flattered by A$3.2M of advance billing, and the FY26 cash flow was supported by receivables collection (down A$1.05M). Underlying cash generation is therefore best judged across FY25 and FY26 combined: about A$4.1M of operating cash flow on A$26.8M of revenue.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts / services

SaMD

Imaging analysis core lab and the former R&D segment (merged into SaMD in the FY25 AR)

FerriScan, FerriSmart, HepaFatScan, HepaFatSmart, LiverSmart, CardiacT2*, MRE central read, VAT/SAT body composition, Resonance Bridge, liver fibrosis R&D

Resonance Clinical

CRO and Australian local-sponsor services

Sun Pharma trial management (A$6.33M contract completed; A$13.8M MASH contract in delivery)

TrialsWest

Site management organisation, 3 clinics

Investigator site services for sponsors (GSK, Pfizer, Novartis, Sanofi, MSD)

Corporate (unallocated)

Head office, listed-company costs, interest income, treasury

—

Revenue by Segment

SegmentFY2024FY2025FY2026

SaMD revenue (AUD Mn)

4.545.277.04

Resonance Clinical revenue (AUD Mn)

3.934.167.54

TrialsWest revenue (AUD Mn)

0.352.664.15

Intersegment elimination (AUD Mn)

-0.23-1.01-2.97

Group revenue (AUD Mn)

8.5911.0715.75

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

SegmentFY2024FY2025FY2026

SaMD PBT (AUD Mn)

2.330.723.28

Resonance Clinical PBT (AUD Mn)

2.230.331.01

TrialsWest PBT (AUD Mn)

0.240.601.01

Corporate PBT (AUD Mn)

-5.43-3.84-4.20

Group PBT (AUD Mn)

-0.63-2.201.10

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2024FY2025FY2026

SaMD PBT margin (%)

51.313.646.6

Resonance Clinical PBT margin (%)

56.87.913.4

TrialsWest PBT margin (%)

69.422.524.4

SaMD YoY revenue growth (%)

—16.033.5

Resonance Clinical YoY revenue growth (%)

—5.881.2

TrialsWest YoY revenue growth (%)

—661.256.1

SaMD share of pre-elimination revenue (%)

51.543.637.6

Resonance Clinical share of pre-elimination revenue (%)

44.634.440.3

TrialsWest share of pre-elimination revenue (%)

4.022.022.1

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (AUD Mn)

3.834.408.5911.0715.75

Revenue growth (%)

1.315.195.028.942.3

Other income (AUD Mn)

0.030.110.210.090.02

Employee benefits expense (AUD Mn)

2.493.113.735.636.43

Consulting & professional services (AUD Mn)

0.240.241.702.854.03

R&D expensed (AUD Mn)

0.720.710.840.960.43

Share-based payments (AUD Mn)

0.010.020.830.190.21

Statutory EBITDA (AUD Mn)

-1.13-0.86-0.13-0.992.34

Normalised EBITDA per AR five-year table (AUD Mn)

-1.12-0.840.70-0.722.55

EBIT / operating income (AUD Mn)

-1.56-1.30-0.69-1.961.39

Finance costs (AUD Mn)

——0.050.320.34

Profit before tax (AUD Mn)

-1.55-1.26-0.63-2.201.10

Income tax benefit (AUD Mn)

0.410.480.800.470.41

Net profit after tax (AUD Mn)

-1.14-0.780.17-1.731.51

Basic EPS (AUD cents)

-0.25-0.170.04-0.380.32

Diluted EPS (AUD cents)

-0.25-0.170.04-0.380.31

Dividends per share (AUD cents)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Statutory EBITDA margin (%)

-29.4-19.6-1.5-9.014.9

Normalised EBITDA margin (%)

-29.3-19.08.1-6.516.2

EBIT margin (%)

-40.6-29.5-8.1-17.78.8

Pre-tax margin (%)

-40.5-28.7-7.3-19.97.0

Net margin (%)

-29.8-17.72.0-15.79.6

Employee costs as % of revenue

65.270.643.450.940.8

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD Mn)

11.6910.9820.2817.8918.74

Cash & equivalents (AUD Mn)

6.786.366.852.984.85

Trade & other receivables (AUD Mn)

1.511.142.323.522.47

Bank debt, current (AUD Mn)

000.320.322.53

Bank debt, non-current (AUD Mn)

002.852.530

Total bank debt (AUD Mn)

003.172.852.53

Lease liabilities (AUD Mn)

0.270.270.520.951.28

Net debt, bank only (AUD Mn)

-6.78-6.36-3.68-0.12-2.32

Net debt incl. leases (AUD Mn)

-6.51-6.09-3.160.83-1.04

Goodwill (AUD Mn)

007.265.275.27

Total intangibles incl. goodwill (AUD Mn)

2.872.719.869.549.25

Deferred consideration, TrialsWest (AUD Mn)

004.000.090.09

Unearned income (AUD Mn)

0.020.010.013.201.23

Total liabilities (AUD Mn)

1.001.059.358.507.63

Total equity (AUD Mn)

10.699.9410.939.3911.11

Working capital (AUD Mn)

7.546.683.141.430.88

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Receipts from customers (AUD Mn)

3.534.338.1113.9714.28

Net operating cash flow (AUD Mn)

-1.46-0.161.391.252.88

R&D tax incentive / income tax received (AUD Mn)

00.890.800.210.73

Capex, PP&E (AUD Mn)

0.120.290.230.440.09

Capitalised development / intangibles (AUD Mn)

0.580.180.150.180.21

Free cash flow, OCF less PP&E less intangibles (AUD Mn)

-2.16-0.621.010.632.58

Acquisition of TrialsWest, net (AUD Mn)

003.563.910

Borrowings drawn (AUD Mn)

003.2000

Borrowings repaid (AUD Mn)

000.030.320.32

Lease principal repaid (AUD Mn)

0.070.080.130.290.31

Dividends paid (AUD Mn)

00000

Cash buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%)

-10.7-7.91.5-18.513.6

ROA (%)

-9.8-7.10.8-9.78.1

ROIC, EBIT x 0.75 / (equity + bank debt − cash) (%)

-29.8-27.3-7.2-15.811.8

Current ratio (x)

10.348.631.511.281.13

Bank debt / equity (x)

000.290.300.23

Bank + lease debt / equity (x)

0.030.030.340.400.34

Net debt / statutory EBITDA (x)

————-0.99

Interest coverage, EBIT / finance costs (x)

——-14.7-6.14.1

Asset turnover, revenue / total assets (x)

0.330.400.420.620.84

Days sales outstanding, trade receivables (days)

100921008750

Largest customer share of revenue (%)

1114453848

Revenue by Region

RegionFY2022FY2023FY2024FY2025FY2026

Asia/Pacific revenue (AUD Mn)

0.330.294.322.7510.07

North America revenue (AUD Mn)

2.582.782.642.033.93

EMEA revenue (AUD Mn)

0.921.331.646.301.75

South America revenue (AUD Mn)

0.0040000

Total (AUD Mn)

3.834.408.5911.0715.75

Region Margins & Growth (%) and Revenue by Region (%)

MetricFY2023FY2024FY2025FY2026

Asia/Pacific YoY growth (%)

-10.41,369.5-36.4266.6

North America YoY growth (%)

7.9-5.2-23.193.8

EMEA YoY growth (%)

44.522.9285.2-72.2

Asia/Pacific share (%)

6.750.324.863.9

North America share (%)

63.130.718.324.9

EMEA share (%)

30.219.056.911.1

Share Price

MetricFY2021FY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD)

0.160.060.040.060.040.04

Share Price & Returns

PeriodReturn

1-year (from about A$0.041 at 1 Jul 2025, the closest verified datapoint)

About +45%

3-year (from A$0.04, Jun 2023)

About +50%

5-year (from A$0.16, Jun 2021)

About −63%

Valuation Multiples

MultipleRHT (FY26 actuals)RHT (FY27 guidance range)

P/E (x)

17.8

Not available (no EPS guidance)

EV / statutory EBITDA (x)

10.5—

EV / normalised EBITDA (x)

9.6

6.8–9.5

EV / sales (x)

1.56

1.1–1.4

P/B (x)

2.42—

P / tangible book (x)

About 14 (NTA 0.12c per share)

—

EV / FCF, company-reported A$2.8M (x)

About 8.8

—

Capital Instruments

InstrumentAmount (AUD Mn)RateSecurityMaturity

NAB secured finance facility

2.53

BBSY + 2.5%

All assets of RHT and TrialsWest

31 Mar 2027

Lease liabilities

1.28 (current 0.23; non-current 1.05)

Implicit

Leased premises

Various; five premises

Analyst Conclusions

Management guidance (FY26 results, 28 Aug 2026)

MetricFY2026 actualFY2027 guidance lowFY2027 guidance high
Revenue (AUD M)15.7517.022.0
Normalised EBITDA (AUD M)2.62.63.6
Normalised EBITDA margin (%)16.215.316.4

Medium term: about A$30M revenue at about 25% EBITDA margin. The aspirational "Project 50:28" target is A$50M revenue by end of FY28.

Consensus: none (no coverage). The guidance range implies flat-to-modest margin progression in FY27. Revenue growth is heavily dependent on the assumed single new CRO win.

Bull case

  1. Operating leverage is proven and scalable. Incremental EBITDA margin was about 25% in FY26 and employee intensity fell 10 points. If the Bridge and AI deliver even part of the claimed 5–10x analysis capacity, SaMD margins (already 46.6% at segment PBT) can rise as metabolic-trial volumes grow against an over-A$12M pipeline.

  2. Structural demand tailwinds. Two approved MASH drugs, GLP-1 trial proliferation and regulatory demand for non-invasive fibrosis biomarkers align directly with RHT's endpoints. North American revenue grew 94% in FY26.

  3. Cheap free option. At about 9.6x trailing normalised EBITDA, about 1.6x EV/sales, net cash and self-funding status, the fibrosis device receives roughly zero value. A positive EPoC readout in early FY27 could re-rate the stock toward MASH-imaging peers.

Bear case

  1. The MASH contract cliff. The A$13.8M contract (A$7.54M, or 48%, of FY26 revenue) completes in early calendar 2027. FY27 guidance already assumes a replacement CRO win that has not been announced. The 2H FY26 slowdown to about breakeven NPAT shows how sensitive earnings are to one trial's economics.

  2. Earnings quality and disclosure. Normalised EBITDA definitions shift between documents (the FY25 base of −A$0.72M vs +A$1.4M). Tax-incentive benefits inflate NPAT. Geographic reclassification is unexplained. The FY26 cash flow was supported by working-capital release (receivables down A$1.05M).

  3. Scale and competitive disadvantage. At A$15.8M revenue with A$4.2M of corporate overhead, RHT is sub-scale against well-funded Perspectum and global core labs. Several patents are lapsing. Refinancing falls due in March 2027. The board lacks diversity. The stock is illiquid with no institutional sponsorship.

Key catalysts and monitorables (next 12 months)

Expected timingCatalyst / monitorable
Early FY27 (late 2026)Liver-fibrosis EPoC readout and regulatory plan
19 Nov 2026AGM: trading update; remuneration report vote; any FY27 guidance commentary
FY27New Resonance Clinical CRO contract announcement, which guidance assumes
By 31 Mar 2027NAB facility refinancing terms
Feb 20271H FY27 results (expected about 26 Feb 2027 per InvestSMART calendar): run-rate vs guidance; MASH trial wind-down
FY27Conversion of the over-A$12M SaMD pipeline; Bridge deployments
FY27Customer concentration below 40%
FY27Any TrialsWest site acquisitions; India and China contract wins
May 2027Expiry of TrialsWest founders' three-year retention commitment

Analyst verdict

Resonance Health has completed a difficult transition. In FY23 it was a stagnant, loss-making single-product imaging company with A$4.4M of revenue. In FY26 it is a cash-generative, profitable three-business platform with A$15.8M of revenue, positive operating cash flow in every quarter and net cash. The strategic logic is sound: a niche, high-margin imaging core lab with genuine reference-standard credibility, attached to Australian CRO and investigator-site capabilities that keep more of each sponsor dollar in the group. Intersegment eliminations of A$3.0M show the cross-referral flywheel working, and the SaMD segment's 46.6% FY26 margin confirms the core remains valuable.

The dossier nonetheless argues for discipline in extrapolation. FY26 profit was front-loaded: roughly A$1.5M NPAT in 1H against breakeven in 2H. Nearly half of revenue came from one Sun Pharma MASH trial that ends in early 2027, after a margin-reducing budget reset. FY27 guidance of A$17–22M revenue and A$2.6–3.6M normalised EBITDA implies little margin expansion and relies on an unannounced CRO win. The NAB facility must be refinanced by March 2027. Disclosure is adequate but uneven, including inconsistent normalised EBITDA and unexplained regional swings.

At about A$27M market capitalisation (about 1.6x EV/sales and under 10x trailing normalised EBITDA), the market appears to price RHT as a small services company with concentration risk. It assigns little value to the automation upside or the fibrosis device. That framing seems broadly fair today. The equity's asymmetry depends on two near-term binary events: a credible replacement CRO contract, and a positive fibrosis EPoC readout.

Verdict: a speculative but improving micro-cap. Fundamental momentum is positive and insider alignment is strong, but customer concentration and execution risk are high. The thesis should be re-underwritten after the EPoC readout and the next CRO contract announcement.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / educationAge

Andrew Harrison

Managing Director & CEO

CEO since 1 Jul 2023; MD since 1 Oct 2025

Founder and MD/CEO of Capitol Health Ltd (ASX: CAJ), MD/CEO Nov 2016 to Jun 2019; former director of Enlitic LLC (US medical AI); M&A, capital markets and turnaround experience; BComm (Hons)

54 (Simply Wall St, 2025)

Benjamin Carruthers

Chief Financial Officer

Since 9 Oct 2023

Former GM of SFM Marine; former Executive Director at KordaMentha; 20+ years in advisory, restructuring and turnaround

—

Mitchell Wells

Company Secretary (part-time consultant) and NED

Director since 28 Feb 2018; MD 1 Jul 2021 to 1 Jul 2023

Lawyer with Australian, US and UK experience; former company secretary of ASX- and Nasdaq-listed companies; LLB, BComm, Dip. Aviation (CPL)

—

Dr Helen Pavitt

VP, Clinical Trials (TrialsWest founder)

Since acquisition (May 2024)

Co-founder of TrialsWest

—

Michelle Davies; Prof. Peter Bremner

TrialsWest co-founders, key leadership roles

Since acquisition

Committed to remain at least three years post-completion

—

“—” = not publicly disclosed.

Board of Directors

DirectorRoleIndependentAppointedBackgroundCommitteesShareholding

Aaron Brinkworth

Non-executive Chair (since 13 Nov 2025)

Yes

27 Mar 2023

22 years at Gilead Sciences incl. Executive Director, Global Patient Solutions and APAC commercial lead; NED of Proteomics International (ASX: PIQ), Atherid Therapeutics, Lixa; BHlthSc, GAICD

Chair, Remuneration; member, Audit & Risk

1,107,647 shares

Andrew Harrison

MD & CEO

No

Director 1 Oct 2025

See above

—

8,000,000 shares plus 11,070,857 loan shares

Mitchell Wells

NED & Company Secretary

No (former executive; paid consultant)

28 Feb 2018

See above

Member, Audit & Risk

2,830,000 shares

Simon Panton

NED

No (substantial shareholder; board since 2009)

5 Oct 2009

Business owner; long-term supporter and major shareholder

Audit & Risk; Remuneration

80,137,174 shares

Dr Travis Baroni

NED

Yes

25 Nov 2016

Applied physics PhD (UWA); industrial R&D; investment banking / ECM

Chair, Audit & Risk; member, Remuneration

1,130,000 shares

Dr David Fuller

NED

Yes

28 Apr 2026

Pharmaceutical physician and pharmacist with 30+ years in drug development; CMO of Dimerix (ASX: DXB); MBBS, B.Pharm (Hons)

Audit & Risk; Remuneration

98,701 shares

Michael Sistenich

NED

Yes

28 Apr 2026

CEO and director of Enlitic Inc. (ASX: ENL), formerly its Chair; ex-CEO of Nohla Therapeutics; ex-NED of Opthea; MSc BioChem

Audit & Risk; Remuneration

Nil

Directors' Remuneration

NameCash salary / feesSTI / bonusNon-monetarySuperannuationEquity-settledTotal

A Harrison (MD & CEO)

433,773125,5209,90030,00044,004643,197

B Carruthers (CFO)

314,78154,5205,31330,00029,374433,988

M Wells (NED / Co Sec / consultant)

232,6250003,426236,051

A Brinkworth (Chair)

78,089009,371087,460

S Panton

58,296006,996065,292

T Baroni

58,296006,996065,292

M Blake (to 13 Nov 2025)

33,134003,976037,110

D Fuller (from 28 Apr 2026)

10,682001,282011,964

M Sistenich (from 28 Apr 2026)

10,682001,282011,964

Total KMP

1,230,358180,04015,21389,90376,8041,592,318

Major Shareholders

HolderSharesApprox. % of ~474.8MSource / date

Simon Panton (NED)

80,137,17416.9

FY26 AR (27 Aug 2026)

Andrew Harrison (incl. 11.07M loan shares)

19,070,8574.0

FY26 AR

Paul Van Dyk

9,250,0311.9

Simply Wall St (2025; may be stale)

Benjamin Carruthers (loan shares)

7,342,5531.5

FY26 AR

William Thompson

6,658,6601.4

Simply Wall St (2025)

Jade Thompson

6,512,7591.4

Simply Wall St (2025)

Harish Garg

6,500,0001.4

Simply Wall St (2025)

Dr Martin Blake (at resignation)

6,464,6771.4

FY26 AR (Nov 2025)

Mitchell Wells

2,830,0000.6

FY26 AR

Dr Travis Baroni

1,130,0000.2

FY26 AR

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypePositioning vs RHTRevenue

SaMD: liver imaging

Perspectum (UK)

Private

LiverMultiScan (cT1, fat, iron); FDA-cleared; US reimbursement; also offers CRO imaging services. The most direct liver-MRI rival in MASH. Raised about US$140M+ by 2023; 192 employees at the abandoned 2021 IPO

—

SaMD: liver stiffness

Resoundant (US)

Private

MR Elastography technology owner; RHT now offers MRE central reads

—

SaMD: non-imaging liver tests

Echosens (FibroScan)

Private

Ultrasound transient elastography; dominant point-of-care non-invasive test for MASH; competes with MRI-based fibrosis

—

Imaging core lab / iCRO

Clario (incl. former Bioclinica)

Private

Global scale imaging core lab

—

Imaging core lab / iCRO

Median Technologies (Euronext Growth: ALMDT)

Listed

Oncology iCRO plus eyonis SaMD

€23.5M CY2025 (+2.6%); backlog €76.6M

Imaging core lab / iCRO

IXICO plc (AIM: IXI)

Listed

Neuroscience imaging biomarkers

£6.5M FY Sep-2025 (+13%); EBITDA −£1.3M

Imaging core lab / iCRO

Calyx, Imaging Endpoints, Radiant Sage, ICON, Parexel, Medpace imaging units

Private or divisions

Full-service imaging within large CROs

—

Scanner OEM tools

Siemens Healthineers, GE HealthCare, Philips

Listed majors

Inline R2* / PDFF / T2* mapping on scanners erodes demand for basic quantification. Analyst characterisation

Segment revenue not disclosed

CRO (Australia)

Novotech, Avance Clinical, IQVIA, George Clinical, Southern Star Research

Private / listed

Established Australian CROs competing for local-sponsor and trial management work. Analyst characterisation

—

Investigator sites (WA / Australia)

Linear Clinical Research (Perth), Paratus Clinical, other SMOs and hospital trial units

Private / not-for-profit

Competition for sponsor site selection and patients. Analyst characterisation

—

“—” = not publicly disclosed.

Peer Comparison FY2027

MetricResonance Health (FY Jun-2026)Median Technologies (CY2025)IXICO (FY Sep-2025)Pro Medicus (FY Jun-2026, adjacent imaging software)

Revenue

A$15.75M

€23.5M

£6.5M

A$261.7M

Revenue growth

+42.3%+2.6%+13%+22.9%

EBITDA margin

14.9% statutory; 16.2% normalised

—

about −20% (EBITDA −£1.3M)

EBIT margin 74.9%

Net margin

9.6%—

Loss

Underlying NPAT A$144.7M (55%)

R&D intensity

2.8% expensed; 4.1% incl. capitalised

———

Recent Developments

Items with nothing to report in the period: * litigation, regulatory enforcement and layoffs.

Company Snapshot

$10.2M

Revenue

1987

Founded

Burswood, Australia

Headquarters

SWOT Analysis

Strengths

  • Reference-standard IP. FerriScan has held FDA, CE and TGA clearance since 2005, plus a 2013 FDA companion-diagnostic clearance with Exjade. More than 70,000 analyses had been performed by FY23.
  • High-margin core. SaMD segment pre-tax margin was 46.6% in FY26 on A$7.04M of revenue (FY26 AR Note 4).
  • Integrated model, with eliminations as evidence. Intersegment eliminations rose from A$0.23M (FY24) to A$2.97M (FY26), so about 16% of segment revenue is internally referred.
  • Self-funding. Operating cash flow was positive in all four FY26 quarters, totalling A$2.88M. Net cash was A$2.3M at 30 Jun 2026, and ASX waived quarterly 4C reporting (Aug 2026).
  • Operating leverage already visible. Employee costs fell from 51% to 41% of revenue, and the incremental EBITDA margin was about 25% (FY26 results).
  • Skin in the game. Insiders hold about a third of the company. Panton holds about 16.9%, and the Chair, CEO and new NEDs have all bought on-market in 2025–26.
  • Regulatory and quality infrastructure. Clearances in the US, EU, UK and Australia, plus ISO 13485.

Weaknesses

  • Customer concentration. One customer was 48% of FY26 revenue (38% in FY25, 45% in FY24).
  • Thin CRO margin. Resonance Clinical's PBT margin was 13.4% in FY26, after a June 2026 budget reset.
  • Corporate overhead. The unallocated corporate segment lost A$4.20M in FY26, 27% of revenue.
  • Stagnant diagnostics. Commercial revenue was flat at A$3.22M in FY25 and FY26; management cites the need for reimbursement.
  • Weak second half. Implied 2H FY26 NPAT was about breakeven against A$1.5M in 1H.
  • Disclosure gaps. Headcount, patents and geographic reclassifications are undisclosed or unexplained; the normalised EBITDA definition is inconsistent between documents.
  • Tight liquidity metrics. The current ratio is 1.13x, with all A$2.53M of bank debt current at 30 Jun 2026.

Opportunities

  • MASH and GLP-1 imaging demand. Rezdiffra reached US$958M in 2025 sales and Wegovy gained MASH approval in Aug 2025, both expanding the need for liver imaging.
  • Liver fibrosis device. The EPoC is fully enrolled with readout due early FY27. Investigational use is targeted from FY27/28. No revenue from it is included in guidance.
  • Automation. The Bridge and AI tooling target 5–10x analysis capacity, supporting the objective of about 25% EBITDA margin at A$30M revenue.
  • SaMD pipeline. Over A$12M of forward orders and bids at FY26, nearer A$13M per the webinar, against A$7.0M of FY26 segment revenue.
  • Geographic expansion. India BD hire and China discussions (1H FY26).
  • SMO roll-up. Management stated intent to pursue accretive site acquisitions, with three sites already profitable or near breakeven.

Threats

  • Replacing the MASH contract. The trial ends in early calendar 2027. FY27 guidance assumes one new CRO win, and none had been announced by 15 Oct 2026.
  • Refinancing. The NAB facility (A$2.53M, BBSY + 2.5%) matures 31 Mar 2027.
  • Competition. Perspectum (well funded, FDA-cleared LiverMultiScan, US reimbursement), Echosens FibroScan and scanner-native mapping.
  • Patent lapses. The FY24–FY26 ARs warn that certain products' patents will lapse in the coming years.
  • FX exposure. Most SaMD revenue is in USD, GBP and EUR, and RHT does not hedge. FX was a A$0.11M loss in FY26.
  • Fibrosis readout risk. A negative or ambiguous EPoC result would remove the main strategic option and could trigger impairment of A$1.09M+ of capitalised fibrosis development.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
9 Apr 2025Chair-elect Brinkworth buys 807,647 shares on-market (about A$30k)Insider alignment
2H FY25 (by Jun 2025)First Sun Pharma CRO trial delivery completedValidates CRO capability
FY25ASO molecular medicine programme ceased; Bentley lab closedPortfolio focus; cost reduction
Jul 2025Third TrialsWest site (Mandurah) lease signed and openedCapacity tripled vs acquisition
6 Aug 202511.15M loan shares issued to CEO and CFO at A$0.036Long-term incentive; potential dilution
Aug 2025Bentley laboratory lease surrenderedFootprint consolidation
28–29 Aug 2025FY25 results: revenue A$11.1M (+29%); statutory NPAT −A$1.73M; receipts A$14.0M (+72%); FY26 guidance A$17M revenue / A$2M EBITDA; about A$1.1M cost savingsTurnaround plan set
1 Sep 2025Updated top-20 shareholder information lodgedDisclosure
1 Oct 2025Andrew Harrison appointed Managing DirectorBoard-level CEO
13 Oct 2025Investor Strategy Day briefing and webinarStrategy articulation
Oct 2025Q1 FY26 Appendix 4C (details not captured)Periodic
13 Nov 2025Dr Martin Blake retires after 18 years; Brinkworth becomes Chair; 2025 AGM remuneration report passes at 92.28%Governance renewal
15 Dec 2025Application for quotation of securitiesCapital management
30 Jan 2026Q2 FY26 4C: multi-year SaMD contracts; fibrosis EPoC nearing completion; Bridge de-identifies PHIPipeline progress
27 Feb 20261H FY26 results: revenue A$8.0M (+53%); NPAT A$1.5M; normalised EBITDA A$1.6M (20%); SaMD pipeline over A$10M; EPoC enrolment complete; India BD hire; China discussions; FY26 guidance maintainedReturn to profit
27 Feb to 2 Mar 202610.87M performance rights issued; 2.33M incentive shares quotedEquity compensation
Mar 2026Receipt of R&D tax incentive refund (A$0.83M for FY25 R&D)Liquidity
27 Mar 2026Panton buys 2.65M shares at A$0.040Insider buying
Apr 2026A$13.8M MASH trial reaches 60-patient recruitment targetDe-risks contracted revenue
28 Apr 2026Dr David Fuller and Michael Sistenich appointed independent NEDsBoard skills in drug development and capital markets
29 Apr 2026Q3 FY26 4CPeriodic
5 May 2026Guidance upgrade: EBITDA about A$2.6M (+30%); revenue trimmed to about A$16M on revenue-recognition timingMargin over volume
22 May 2026Fuller buys 98,701 shares at A$0.040Insider buying
9 Jun 2026Liver Fibrosis Device Progress and FY26 Portfolio webinar; commercial launch targeted FY27/28; 400+ sites in 48 countriesPipeline visibility; shares +20% on the day
Jun 2026MASH trial budget reset for slower recruitment and higher screen failuresLower trial gross margin
13 Jul 2026Panton buys 1.64M shares at A$0.045Insider buying
24 Jul 2026Q4 FY26 4C: receipts A$4.0M; operating cash flow +A$0.7M; cash A$4.8M; positive operating cash flow in all four quartersCash discipline
12 Aug 2026ASX confirms quarterly 4C reporting no longer requiredSignals financial maturity
19 Aug 2026FY26 results webinar notice—
27–28 Aug 2026FY26 Appendix 4E and Annual Report: revenue A$15.75M (+42%); NPAT A$1.51M; normalised EBITDA A$2.6M; FY27 guidance A$17–22M revenue / A$2.6–3.6M EBITDA; NAB facility maturity Mar 2027 flaggedKey annual reset
31 Aug 2026Appendix 4G and Corporate Governance Statement lodgedGovernance
Sep 2026AGM set for 19 Nov 2026; director nominations closed 7 Oct 2026Upcoming catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue rose from AUD 3.8 Mn in FY2022 to AUD 15.8 Mn in FY2026.
Resonance Health Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue3.84.48.611.115.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. FY26 Appendix 4E & Annual Report (27–28 Aug 2026) (investorpa.com)
  2. FY26 results announcement (28 Aug 2026) (announcements.asx.com.au)
  3. FY25 Appendix 4E & Annual Report (29 Aug 2025) (announcements.asx.com.au)
  4. FY24 Appendix 4E & Annual Report (30 Aug 2024) (announcements.asx.com.au)
  5. FY23 Appendix 4E & Annual Report (30 Aug 2023) (announcements.asx.com.au)
  6. 1H FY26 results (27 Feb 2026) (bulletin.webull.com)
  7. Q4 FY26 Appendix 4C (24 Jul 2026) (announcements.asx.com.au)
  8. Profit Guidance Upgrade (5 May 2026) (investorpa.com)
  9. Liver Fibrosis Device Progress webinar (9 Jun 2026) (investorpa.com)
  10. Cessation of Quarterly Reporting (12 Aug 2026) (bulletin.webull.com)
  11. MD appointment (1 Oct 2025) (bulletin.webull.com)
  12. Investor Strategy Day (13 Oct 2025) (bulletin.webull.com)
  13. FY25 results presentation summary (investorpa.com)
  14. FY26 earnings call highlights (Investing.com) (ca.investing.com)
  15. TrialsWest acquisition (Clinical Trials Arena) (clinicaltrialsarena.com)
  16. TrialsWest acquisition (SmallCaps) (smallcaps.com.au)
  17. Sun Pharma agreement (SmallCaps) (smallcaps.com.au)
  18. A$13.775M contract (TipRanks) (tipranks.com)
  19. UWA Research Impact (FerriScan origins) (researchimpact.uwa.edu.au)
  20. FerriSmart FDA clearance (Stockhead) (stockhead.com.au)
  21. FerriSmart FDA clearance (SmallCaps) (smallcaps.com.au)
  22. Company history (Stockhead) (stockhead.com.au)
  23. Business News company page (businessnews.com.au)
  24. Incorporation date (IBISWorld) (ibisworld.com)
  25. Ownership (Simply Wall St) (simplywall.st)
  26. Market data (PitchBook) (pitchbook.com)
  27. Share price and director trades (InvestSMART) (investsmart.com.au)
  28. Shares on issue (Stockopedia) (stockopedia.com)
  29. ISIN and OTC line (MarketScreener) (marketscreener.com)
  30. AGM notice (Kalkine) (kalkinemedia.com)
  31. Fibrosis device coverage (StockWireX) (stockwirex.com)
  32. FY26 results coverage (StockWireX) (stockwirex.com)
  33. Clinical trial imaging market (Towards Healthcare) (towardshealthcare.com)
  34. Clinical trial imaging market (Mordor via GII) (giiresearch.com)
  35. MTPConnect clinical trials sector reports (mtpconnect.org.au)
  36. MASH pharmacotherapy review (PMC) (ncbi.nlm.nih.gov)
  37. MASH market takeaways (Managed Healthcare Executive) (managedhealthcareexecutive.com)
  38. Wegovy MASH approval (Fierce Pharma) (fiercepharma.com)
  39. IXICO FY25 results (ixico.com)
  40. Median Technologies 2025 results (BioSpace) (biospace.com)
  41. Pro Medicus FY26 results (announcements.asx.com.au)
  42. Perspectum profile (IPOScoop) (iposcoop.com)
  43. Clinical trial imaging competitor list (CB Insights / Radiant Sage) (cbinsights.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.